Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREST-HD: Creatine for Huntington's Disease
NCT00026988Phase 2Completed
- Sponsor
- National Center for Complementary and Integrative Health
- Start
- Oct 2001
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Huntington's disease (HD) comparing Creatine with Placebo (2 arms). Primary endpoint: Safety and Tolerability. Started Oct 2001; status: completed.
02
Drugs
creatine
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT00026988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026988.